Concentration-effect, incidence and mechanism of nevirapine hepatotoxicity

American Journal of Pharmacology and Toxicology

Volumn 8, Issue 1, 2013, Pages 20-30

  Elias, Adikwu ^a   Nelson, Brambaifa ^a  

^a UNIVERSITY OF PORT HARCOURT   (Nigeria)

Author keywords

Concentration; Liver; Nevirapine; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ARTICLE; CHOLESTATIC HEPATITIS; CLINICAL EVALUATION; CONCENTRATION RESPONSE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSTROPHY; FATIGUE; FULMINANT HEPATIC FAILURE; HEPATITIS; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; JAUNDICE; LEUKOPENIA; LIVER FUNCTION; LIVER NECROSIS; LIVER TOXICITY; MITOCHONDRIAL TOXICITY; MORTALITY; NAUSEA; NONHUMAN; PATHOGENESIS; PRURITUS; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TREATMENT DURATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 84876839128     PISSN: 15574962     EISSN: 15574970     Source Type: Journal    
DOI: 10.3844/ajptsp.2013.20.30     Document Type: Article

References (86)

1. Adaramoye, O.A., O.A. Adesanoye, O.M. Adewumi and O. Akanni, 2012. Studies on the toxicological effect of nevirapine, an antiretroviral drug, on the liver, kidney and testis of male Wistar rats. Hum. Exp. Tox., 13: 676-685. DOI: 10.1177/0960327111424304.
2. Adewale, O.A., O.O. Jubril, H.I. Olwasegun, H.A. Selinot and A.R. Ayoola, 2012. Effects of a single pill 3-drug combination of lamivudine, nevirapine and zidovudine on blood parameters and liver histology in female wistar rats. Am. J. Med. Med. Sci., 2: 71-74. DOI: 10.5923/j.ajmms.20120204.02.
3. Almond, L.M., M. Boffito, P.G. Hoggard, S. Bonora and R. Raiteri et al., 2004. The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res. Hum. Retroviruses, 20: 716-722. PMID: 15307917.
4. Baichi, M., 2003. Nevirapine hepatotoxicity: Case report and discussion. Med. Forum.
5. Bera, E., D. Naidoo and M. Williams, 2012. Maternal deaths following nevirapine-based antiretroviral therapy. S. Afr. J. HIV Med., 13: 196-197. DOI: 10.7196/SAJHIVMED.869.
6. Bissell, D.M., G.J. Gores, D.J. Laskin and J.H. Hoofnagle, 2001. Drug-induced liver injury: Mechanisms and test systems. Hepatology, 33: 1009-1013.PMID: 11283870.
7. Boelsterli, U.A., 2002. Mechanisms of NSAID-induced hepatotoxicity: Focus on nimesulide. Drug. Saf., 25: 633-648.PMID: 12137558.
8. Bruck, S., S. Witte, J. Brust, D. Schuster and F. Mosthaf et al., 2008. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur. J. Med. Res., 13: 343-348.PMID: 18700192.
9. Bundow, D., L. Rosoff and D.M. Abonlafia, 2001. Optimal treatment of nevirapine-associated hepatotoxicity remains uncertain. AID Read., 11: 577-580.PMID: 11789021.
10. Buyse, S., E. Vibert, M. Sebagh, T. Antonini and P. Ichei et al., 2006. Liver transplantation for fulminant hepatitis related to nevirapine therapy. Liver Transpl., 12: 1880-1882.PMID: 17133571.
11. Cattelan, A.M., E. Erne, A. Salatin, M. Trenvezoli and G. Carretta, 1999. Severe hepatic failure related to nevirapine treatment. Clin. Infect. Dis., 29: 455-456.PMID: 10476768.
12. CDC, 2001. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures-Worldwide, 1997-2000. MMRN., 49: 1153-1156.
13. Cheeseman, S.H., S.E. Hattox, M.M. McLaughlin, R.A. Koup and C. Andrews et al., 1993. Pharmacokinetics of nevirapine: Initial single-risingdose study in humans. Antimicrob. Agents Chemother., 37: 178-182.PMID: 8452345.
14. Chu, K.M., A.M. Boulle, N. Ford, E. Goemaere and V. Asselman et al., 2010. Nevirapine-associated early hepatotoxicity: Incidence, risk factors and associated mortality in a primary care ART programme in South Africa. PLoS One, 5: 9183-9183. DOI: 10.1371/journal.pone.0009183.
15. Clarke, S., P. Harrington, C. Condon, D. Kelleher and O.P. Smith et al., 2000. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy. Int. J. STD AIDS, 11: 336-337.PMID: 10824944.
16. Dailly, E., E. Billaud, V. Reliquet, S. Breurec and P. Perre et al., 2004. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur. J. Clin. Pharmacol., 60: 343-348.PMID: 15156302.
17. Deschamps, D., C. Fisch, B. Fromenty, A. Berson and C. Degott et al., 1991. Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids. Possible role in the development of Reye's syndrome. J. Pharmacol. Exp. Ther., 259: 894-904.PMID: 1941634.
18. Dieterich, T.D., P.A. Robison, J. Love and J.O. Stern, 2004. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin. Infect. Dis., 38: 508-509.PMID: 14986279.
19. Dong, B.J., Y. Zheng, M.D. Hughes, A. Frymoyer and D. Verotta et al., 2012. Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS, 26: 833-841. DOI: 10.1097/QAD.0b013e328351a521.
20. Dykens, J.A. and Y. Will, 2007. The significance of mitochondrial toxicity testing in drug development. Drug. Discov. Today, 12: 777-785. DOI: 10.1016/j.drudis.2007.07.013.
21. Emejulu A.A., C. OUjowundu, C.U. Igwe and V.A. Ouwuliri, 2010. Hepatotoxicity of antiretroviral drugs in HIV seropositive Nigerian patients Aust. J. Basic Applied Sci., 4: 4275-4278.
22. Erickson, D.A., G. Mather, W.F. Trager, R.H. Levy and J.J. Keirns, 1999. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug. Metab. Dispos., 27: 1488-1495.PMID: 10570031.
23. Eshleman, S.H., L.A. Guay, A. Mwatha, S.P. Cunningham and E.R. Brown et al., 2009. Comparison of Nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after singledose nvp prophylaxis: HIVNET 012. AIDS Res. Retroviruses, 20: 595-599.PMID: 15242535.
24. Fromenty, B. and D. Pessayre, 1995. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol. Ther., 67: 101-154.PMID: 7494860.
25. Gao, S.E., X.E. Gui, L.P. Deng and Y.X. Zhang, 2010. Nevirapine related hepatotoxicity: The prevalence and risk factors in a cohort of ART naive Han Chinese with AIDS. Zhonghua. Gan. Zang. Bing. Za. Zhi., 18: 689-693. DOI: 10.3760/cma.j.issn.1007-3418.2010.09.011.
26. Gokengin, D and T. Yamazahan, 2002. Hepatic adverse events during highly active antiretroviral therapy containing nevirapine: A case report. Ann. Clin. Microbiol. Antimicrob., 1: 1-1. DOI: 10.1186/1476- 0711-1-1.
27. Grattagliano, I., P. Portincasa, V.O. Palmieri and G. Palasciano, 2002. Overview on the mechanisms of drug-induced liver cell death. Ann. Hepatol., 1: 162-168.PMID: 15280801.
28. Haas, D.W., 2005. Pharmacogenomics and HIV therapeutics. J. Infect. Dis., 191: 1397-1400.PMID: 15809895.
29. Harris, M. and J.S. Montaner, 2000. Clinical uses of nonnucleoside reverse transcriptase inhibitors. Rev. Med. Virol., 10: 217-229.PMID: 10891870.
30. Jamisse, L., J. Balkus, J. Hitti, S. Gloyd and R. Manuel et al., 2007. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J. Acquir. Immune Defic. Syndr., 44: 371-376.PMID: 17259905.
31. Johnson, S. and J.G. Baraboutis, 2000. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA, 284: 2722-2723.PMID: 11105175.
32. Jonckheere, S., J. Yombi, L. Belcher and A. Vicent, 2012. Nevirapine-associated liver toxicity and hypersensitivity reactions in a cohort of HIV-1- infected patients,clinical analysis. Retrovirology, 1: 10-10. DOI: 10.1186/1742-4690-9-S1-P10.
33. Kappelhoff, B.S., F.V. Leth, P.A. Robinson, T.R. MacGregor and E. Baraldi et al., 2005. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir. Ther., 10: 489-498.PMID: 16038474.
34. Kayode, A.A., T.O. Kayode, O.A. Areyeun and M.C. Stephen, 2011. Hematological and hepatic enzyme alterations associated with acute administration of antiretroviral drugs. Asian J. Pharmacol. Toxicol., 6: 293-302. DOI: 10.3923/pt.2011.293.203.
35. Knudtson, E., M. Para, H. Boswell and P. Fan-Havard, 2003. Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. Obstet. Gynecol., 101: 1094-1097.PMID: 12738113.
36. Kontorinis, N. and D. Dieterich, 2003. Hepatotoxicity of antiretroviral therapy. AIDS Rev., 5: 36-43.PMID: 12875106.
37. Kuritkes, D.R., 2004. Preventing and managing antiretroviral drug resistance. AIDS Patients Care STDS, 18: 259-273.PMID: 15186710.
38. Lee, W.M., 2003. Drug-induced hepatotoxicity. N. Engl. J. Med., 349: 474-485. DOI: 10.1056/NEJMra021844.
39. Leist, M., F. Gantner, G. Kunstle and A. Wendel, 1998. Cytokine-mediated hepatic apoptosis. Rev. Physiol. Biochem. Pharmacol., 133: 109-155.PMID: 9600012.
40. Ma, Q., O.O. Okusanya, P.F. Smith, R. Dicenzo and J.C. Slish et al., 2005. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert. Opin. Drug. Metab. Toxicol., 1: 473-485.PMID: 16863456.
41. Maat, M.M.D., R.A. Mathot, A.I. Veldkamp, A.D. Huitma and J.W. Mulder et al., 2002. Hepatotoxicity following nevirapine-containing regimens in HIV-1- infected individuals. Pharmacol. Res., 46: 295-300.PMID: 12220974.
42. Maat, M.M.D., R.T. Heine, E.C.V. Gorp, J.W. Mulder and A.T. Mairuhu et al., 2003. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS, 17: 2209-2214.PMID: 14523278.
43. Magiolo, F., C. Arici, M. Alriodi, D. Ripamonti and G. Quinzan et al., 2007. Reasons for discontinuation of nevirapine-containing HAART: Results from an unselected population of a large clinical cohort. J. Antimicrob. Chemother., 59: 569-572.PMID: 17255141.
44. Manfred, H., 2001. Nevirapine and postexposure prophylaxis for human immunodeficiency virus. JAMA, 285: 883-883. DOI: 10.1001/jama.285.7.879.
45. Maniar, J.K., S.R. Shah, R. Verma, R. Kamath and P. Gupta et al., 2006. Nevirapine-induced fulminant hepatitis. J. Assoc. Physicians. Ind., 54: 957-958.PMID: 17334017.
46. Martin, A.M., D. Nolan, I. James, P. Cameron and J. Keller et al., 2005. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4. T-cell counts. AIDS, 19: 97-99.PMID: 15627041.
47. Masubuchi, Y., S. Kano and T. Horie, 2006. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology, 222: 233-239.PMID: 16621215.
48. McKoy, J.M., C.L. Bennett, M.H. Scheetz, V. Differding and K.L. Kimberly et al., 2009. Hepatotoxicity associated with long-versus short-course HIVprophylactic nevirapine use: A systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. Drug Saf., 32: 147-158.PMID: 19236121, DOI: 10.2165/00002018-200932020-00007.
49. Mens, H. and T.L. Katzenstein, 2005. Hepatic failure due to nevirapine treatment for HIV Infection. Ugeskr Laeger., 167: 4359-4359.PMID: 16287519.
50. Meyssonnier, V., D. Costagliola and P.E. Caumes, 2008. Nevirapine-associated toxicity in Niger. HIV Med., 9: 62-63. DOI: 10.1111/j.1468-1293.2008.00516.x
51. Mirochnick, M., T. Fenton, P. Gagnier, J. Pav and M. Gwynne et al., 1998. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS clinical trials group protocol 250. Team. J. Infect. Dis., 178: 368-374.PMID: 9697716.
52. Moyle, G., 2000. Toxicity of antiretroviral nucleoside and nucleotide analogues: Is mitochondrial toxicity the only mechanism? Drug. Saf., 23: 467-781.PMID: 11144657.
53. Mratinez, E., J.L. Blanco, J.A. Arnaiz, J.B. Perez-Cuevas and A. Mocroft et al., 2001. Hepatotoxicity in HIV- 1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS, 15: 1261-1268.PMID: 11426070.
54. Murphy, R. and J. Montaner, 1996. Drug evaluations anti-infectives: Nevirapine: A review of its development, pharmacological profile and potential for clinical use. Exp. Opin. Invest Drug., 5: 1183-1199. DOI: 10.1517/13543784.5.9.1183.
55. Nunez, M., D. Gonzalez-Requena, J. Gonzalez-Lahoz and V. Soriano, 2003. Short communication: Interactions between nevirapine plasma levels, chronic hepatitis C and the development of liver toxicity in HIV-infected patients. AIDS Res. Hum. Retroviruses, 19: 187-188.PMID: 12689410.
56. Patel, S.M., S. Johnson, S.M. Belknap, J. Chan and B.E. Sha et al., 2004. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J. Acquir. Immune Defic. Syndr., 35: 120-125.PMID: 14722442.
57. Pauli-Magnus, C., B. Stieger, Y. Meier, G.A. Kullak- Ublick and P.J. Meier, 2005. Enterohepatic transport of bile salts and genetics of cholestasis. J. Hepatol., 43: 342-357.PMID: 15975683.
58. Pessayre, D., A. Mansouri, D. Haouzi and B. Fromenty, 1999. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol. Toxicol., 15: 367-373.PMID: 10811531.
59. Pessayre, D., B. Fromenty, A. Mansouri and A. Berson, 2007. Hepato Toxicity Due to Mitochondrial Injury. In: Drug-Induced Liver Disease, Kaplowitz, N. and L.D. DeLeve (Eds.), Inform Healthcare, New York, ISBN-10: 0849398967, pp: 49-84.
60. Pilliero, P.J. and B. Purdy, 2001. Nevirapine-induced hepatitis: A case series and review of the literature. AIDS Read., 11: 379-382.PMID: 11494710.
61. Podzamcer, D. and E. Fumero, 2001. The role of nevirapine in the treatment of HIV-1 disease. Exp. Opin. Pharmacother., 2: 2065-2078.PMID: 11825335.
62. Prakash, M., V. Poreddy, L. Tiyyagura and M. Bonacini, 2001. Jaundice and hepatocellular damage associated with nevirapine therapy. Am. J. Gastroenterol., 96: 1571-1573.PMID: 11374701.
63. Reiter, G.S., 1997. Hepatitis in an HIV-infected man. AIDS Clin. Care, 9: 78-81.PMID: 11364758.
64. Requena, D.G.D., M. Nunez, I. Jimenez-Nacher and V. Soriano, 2002. Liver toxicity caused by nevirapine. AIDS, 16: 290-291.PMID: 11807315.
65. Russmann, S., G.A. Kullak-Ublick and I. Grattagliano, 2009. Current concepts of mechanisms in druginduced hepatotoxicity. Curr. Med. Chem., 16: 3041-3053.PMID: 19689281.
66. Shahar, E., N. Krivoy, S. Weltfriend and S. Pollach, 2004. Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine. J. Inf. Dis., 57: 212-213.PMID: 15507779.
67. Smith, P.F., R. DiCenzo and G.D. Morse, 2001. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin. Pharmacokinet., 40: 893-905.PMID: 11735608.
68. Soriano, V., M. Puoti, P. Garcia-Gasco, K.J. Rockstroh and Y. Benhamou et al., 2008. Antiretroviral drugs and liver injury. AIDS, 22: 1-13.PMID: 18090386.
69. Spahn-Langguth, H. and L.Z. Benet, 1992. Acyl glucuronides revisited: Is the glucuronidation process a toxification as well as a detoxification mechanism? Drug. Metab. Rev., 24: 5-47.PMID: 1555494.
70. Spengler, U., M. Lichterfeld and J.K. Rockstroh, 2002. Antiretroviral drug toxicity--a challenge for the hepatologist? J. Hepatol., 36: 283-294.PMID: 11830343.
71. Stern, J.O., P.A. Robinson, J. Love, S. Lanes and M.S. Imperiale et al., 2003. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J. Acquir. Immune Defic. Syndr., 34: 21-33.PMID: 14562855.
72. Stohr, W., D. Back, D. Dunn, C. Sabin and A. Winston et al., 2008. Factors influencing efavirenz and nevirapine plasma concentration: Effect of ethnicity, weight and co-medication. Antivir. Ther., 13: 675-685. PMID: 18771051.
73. Sule, O.J., Godwin, J. and A.I. Nnopu, 2012. Biochemical investigation of hepatotoxic effects of antiretroviral drugs on wistar Albino rats. J. Phys. Pharm. Adv., 2: 171-175.
74. Sulkowski, M.S., D.L. Thomas, S.H. Mehta, R.E. Chaisson and R.D. Moore, 2002. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology, 35: 182-189.PMID: 11786975.
75. Taiwo, B.O., 2006. Nevirapine toxicity. Int. J. STD AIDS, 17: 364-369.PMID: 16734954.
76. Timmermans, S., C. Tempelman, M.H. Godfried, J. Nellen and J. Dieleman et al., 2005. Nelfinavir and nevirapine side effects during pregnancy. AIDS, 19: 795-799.PMID: 15867493.
77. Torti, C., S. Costarelli, A.D. Silvestri, E. Quiros-Roldan and G. Lapadula et al., 2007. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. Drug. Saf., 30: 1161-1169. PMID: 18035868.
78. Trost, L.C. and J.J. Lemasters, 1996. The mitochondrial permeability transition: A new pathophysiological mechanism for Reye's syndrome and toxic liver injury. J. Pharmacol. Exp. Ther., 278: 1000-1005.PMID: 8819478.
79. Umar, R.A., S.W. Hassan, M.J. Ladan and I.K. Matazu and B. Shehu, 2008. Adverse hepatic effects associated with administration of antiretroviral drugs (nevirapine, lamivudine and stavudine) to albino rats: Implication for management of patients with HIV/AIDS. Asian J. Biochem., 3: 19-25.
80. USFDA, 2005. Center for drug evaluation and research. U.S. Food and Drug Administration.
81. Vanleth, F., S. Andrews, B. Grinsztejn, E. Wilkins and M.K. Lazanas et al., 2005. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS, 19: 463-471.PMID: 15764851.
82. Veldkamp, A.I., G.J. Weverling, J.M. Lange, J.S. Montaner and P. Reiss et al., 2001. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS, 15: 1089-1095.PMID: 11416710.
83. Vogel, M., N. Bertram, J.C. Wasmuth, C. Wyen and E. Voigt et al., 2009. Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals. J. Antimicrob. Chemother., 63: 988-991.PMID: 19270314.
84. Vries-Sluijs, T.E.D., J.P. Dieleman, D. Arts, A.D. Huitema and J.H. Beijnen et al., 2003. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin. Pharmacokinet., 42: 599-605.PMID: 12793844.
85. Wang, J., H. Kou, Q. Fu, Y. Han and Z. Qiu, 2011. Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in chinese patients with HIV infection. PLoS One, 6: 26739-26739. DOI: 10.1371/journal.pone.0026739.
86. WHO, 2006. The World Health Report 2006: Working Together for Health. 1st Edn., World Health Organization, Geneva, ISBN-10: 241563176, pp: 209.